{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T21:19:49Z","timestamp":1790630389773,"version":"4.1.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,29]]},"DOI":"10.7759\/cureus.95675","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T15:26:58Z","timestamp":1761751618000},"source":"Crossref","is-referenced-by-count":2,"title":["The Future of Bladder Cancer Therapies: Integrating Hydrogel Scaffolds for Epigenetic Regulator Delivery"],"prefix":"10.7759","author":[{"given":"Kayode A","family":"John","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augustine O","family":"Odibo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliaa M","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Modinat","family":"Abayomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Favour M","family":"Awah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent U","family":"Barrah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"GLOBOCAN 2022. bladder cancer 9th most common worldwide. (2024). Accessed: August 12, 2025: https:\/\/worldbladdercancer.org\/news_events\/globocan-2022-bladder-cancer-is-the-9th-most-commonly-diagnosed-worldwide\/."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.4103\/0970-1591.166445","article-title":"Non-muscle invasive bladder cancer risk stratification","volume":"31","author":"Isharwal S","year":"2015","unstructured":"Isharwal S, Konety B. Non-muscle invasive bladder cancer risk stratification. Indian J Urol. 2015, 31:289-96. 10.4103\/0970-1591.166445","journal-title":"Indian J Urol"},{"key":"ref3","unstructured":"AUA 2023. intermediate risk NMIBC: surveillance and treatment challenges. (2023). Accessed: August 12, 2025: https:\/\/www.urotoday.com\/conference-highlights\/aua-2023\/aua-2023-bladder-cancer\/144082-aua-2023-intermediate-risk-nmi...."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.12.033","article-title":"European Association of Urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC guidelines panel","volume":"79","author":"Sylvester RJ","year":"2021","unstructured":"Sylvester RJ, Rodr\u00edguez O, Hern\u00e1ndez V, et al.. European Association of Urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC guidelines panel. Eur Urol. 2021, 79:480-8. 10.1016\/j.eururo.2020.12.033","journal-title":"Eur Urol"},{"key":"ref5","unstructured":"FDA approves intravesical mitomycin for recurrent, low-grade, intermediate-risk NMIBC. (2025). Accessed. August 12, 2025: https:\/\/www.onclive.com\/view\/fda-approves-intravesical-mitomycin-for-recurrent-low-grade-intermediate-risk-nmibc."},{"key":"ref6","unstructured":"FDA ODAC votes 5 to 4 against UGN-102 for recurrent LG-IR-NMIBC. (2025). Accessed. August 12, 2025: https:\/\/www.targetedonc.com\/view\/fda-odac-votes-4-to-5-against-ugn-102-for-recurrent-lg-ir-nmibc."},{"key":"ref7","unstructured":"UroGen Pharma. U.S. FDA approves UroGen\u2019s ZUSDURI(TM) (mitomycin) for intravesical solution as the first and only medication for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). (2025). Accessed: August 12, 2025: https:\/\/investors.urogen.com\/static-files\/a8e3e9ca-d7f3-4d3d-ab06-86956c689f7e."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.33590\/emj\/HRLG7780","article-title":"Advancements in hydrogel-based therapies as non-surgical alternatives for urothelial carcinoma: ongoing research and new insights","volume":"10","author":"Jinks J","year":"2025","unstructured":"Jinks J. Advancements in hydrogel-based therapies as non-surgical alternatives for urothelial carcinoma: ongoing research and new insights. Eur Med J. 2025, 10:15-26. 10.33590\/emj\/HRLG7780","journal-title":"Eur Med J"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15122724","article-title":"Local drug delivery in bladder cancer: advances of nano\/micro\/macro-scale drug delivery systems","volume":"15","author":"Marchenko IV","year":"2023","unstructured":"Marchenko IV, Trushina DB. Local drug delivery in bladder cancer: advances of nano\/micro\/macro-scale drug delivery systems. Pharmaceutics. 2023, 15:2724. 10.3390\/pharmaceutics15122724","journal-title":"Pharmaceutics"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1177\/23523735241304348","article-title":"North American study and meta-analysis evaluating performance of Bladder EpiCheck(\u00ae), a FDA cleared test, in non-muscle invasive bladder cancer recurrence","volume":"10","author":"Fleshner N","year":"2024","unstructured":"Fleshner N, Grossman HB, Berglund R, et al.. North American study and meta-analysis evaluating performance of Bladder EpiCheck(\u00ae), a FDA cleared test, in non-muscle invasive bladder cancer recurrence. Bladder Cancer. 2024, 10:278-89. 10.1177\/23523735241304348","journal-title":"Bladder Cancer"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2023.1258666","article-title":"Research progress of biomaterials and innovative technologies in urinary tissue engineering","volume":"11","author":"Duan L","year":"2023","unstructured":"Duan L, Wang Z, Fan S, Wang C, Zhang Y. Research progress of biomaterials and innovative technologies in urinary tissue engineering. Front Bioeng Biotechnol. 2023, 11:1258666. 10.3389\/fbioe.2023.1258666","journal-title":"Front Bioeng Biotechnol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30147-9","article-title":"Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial","volume":"21","author":"Kleinmann N","year":"2020","unstructured":"Kleinmann N, Matin SF, Pierorazio PM, et al.. Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial. Lancet Oncol. 2020, 21:776-85. 10.1016\/S1470-2045(20)30147-9","journal-title":"Lancet Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1478394","article-title":"Hydrogel-based formulations for urothelial cancer therapy","volume":"15","author":"Chang M","year":"2024","unstructured":"Chang M, Chi C, Zheng Z, Zhang M, Lv J, Wang X. Hydrogel-based formulations for urothelial cancer therapy. Front Pharmacol. 2024, 15:1478394. 10.3389\/fphar.2024.1478394","journal-title":"Front Pharmacol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000004296","article-title":"Primary chemoablation of recurrent low-grade intermediate-risk nonmuscle-invasive bladder cancer with UGN-102: a single-arm, open-label, phase 3 trial (ENVISION)","volume":"213","author":"Prasad SM","year":"2025","unstructured":"Prasad SM, Shishkov D, Mihaylov NV, et al.. Primary chemoablation of recurrent low-grade intermediate-risk nonmuscle-invasive bladder cancer with UGN-102: a single-arm, open-label, phase 3 trial (ENVISION). J Urol. 2025, 213:205-16. 10.1097\/JU.0000000000004296","journal-title":"J Urol"},{"key":"ref15","unstructured":"UroGen Pharma. UroGen announces 24-month duration of response of 72.2% from the pivotal phase 3 ENVISION trial of ZUSDURI, the first and only FDA-approved medicine for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. (2025). Accessed: August 12, 2025: https:\/\/investors.urogen.com\/node\/11111\/pdf."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003645","article-title":"Treatment of low-grade intermediate-risk nonmuscle-invasive bladder cancer with UGN-102 \u00b1 transurethral resection of bladder tumor compared to transurethral resection of bladder tumor monotherapy: a randomized, controlled, phase 3 trial (ATLAS)","volume":"210","author":"Prasad SM","year":"2023","unstructured":"Prasad SM, Huang WC, Shore ND, et al.. Treatment of low-grade intermediate-risk nonmuscle-invasive bladder cancer with UGN-102 \u00b1 transurethral resection of bladder tumor compared to transurethral resection of bladder tumor monotherapy: a randomized, controlled, phase 3 trial (ATLAS). J Urol. 2023, 210:619-29. 10.1097\/JU.0000000000003645","journal-title":"J Urol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000002350","article-title":"Durability of response to primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel: OLYMPUS trial final report","volume":"207","author":"Matin SF","year":"2022","unstructured":"Matin SF, Pierorazio PM, Kleinmann N, et al.. Durability of response to primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel: OLYMPUS trial final report. J Urol. 2022, 207:779-88. 10.1097\/JU.0000000000002350","journal-title":"J Urol"},{"key":"ref18","unstructured":"Treatment of adult patients with low-grade intermediate-risk non-muscle invasive bladder cancer. (2025). Accessed. August 12, 2025: https:\/\/www.fda.gov\/media\/186563\/download."},{"key":"ref19","unstructured":"FDA\u2019s ODAC votes against risk\/benefit profile of UGN-102 in recurrent low-grade, intermediate-risk NMIBC. (2025). Accessed. August 12, 2025: https:\/\/www.onclive.com\/view\/fda-s-odac-votes-against-risk-benefit-profile-of-ugn-102-in-recurrent-low-grade-intermed...."},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2024.1528658","article-title":"Recent advances in innovative biomaterials for promoting bladder regeneration: processing and functionalization","volume":"12","author":"Zhang Y","year":"2024","unstructured":"Zhang Y, Ding F, Han J, Wang Z, Tian W. Recent advances in innovative biomaterials for promoting bladder regeneration: processing and functionalization. Front Bioeng Biotechnol. 2024, 12:1528658. 10.3389\/fbioe.2024.1528658","journal-title":"Front Bioeng Biotechnol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2004.02.055","article-title":"Bladder acellular matrix as a substrate for studying in vitro bladder smooth muscle-urothelial cell interactions","volume":"26","author":"Brown AL","year":"2005","unstructured":"Brown AL, Brook-Allred TT, Waddell JE, et al.. Bladder acellular matrix as a substrate for studying in vitro bladder smooth muscle-urothelial cell interactions. Biomaterials. 2005, 26:529-43. 10.1016\/j.biomaterials.2004.02.055","journal-title":"Biomaterials"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s11934-015-0567-x","article-title":"Silk fibroin scaffolds for urologic tissue engineering","volume":"17","author":"Sack BS","year":"2016","unstructured":"Sack BS, Mauney JR, Estrada CR Jr. Silk fibroin scaffolds for urologic tissue engineering. Curr Urol Rep. 2016, 17:16. 10.1007\/s11934-015-0567-x","journal-title":"Curr Urol Rep"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0056237","article-title":"Evaluation of silk biomaterials in combination with extracellular matrix coatings for bladder tissue engineering with primary and pluripotent cells","volume":"8","author":"Franck D","year":"2013","unstructured":"Franck D, Gil ES, Adam RM, Kaplan DL, Chung YG, Estrada CR Jr, Mauney JR. Evaluation of silk biomaterials in combination with extracellular matrix coatings for bladder tissue engineering with primary and pluripotent cells. PLoS One. 2013, 8:e56237. 10.1371\/journal.pone.0056237","journal-title":"PLoS One"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2022.100388","article-title":"The application of 3D bioprinting in urological diseases","volume":"16","author":"Xu K","year":"2022","unstructured":"Xu K, Han Y, Huang Y, Wei P, Yin J, Jiang J. The application of 3D bioprinting in urological diseases. Mater Today Bio. 2022, 16:100388. 10.1016\/j.mtbio.2022.100388","journal-title":"Mater Today Bio"},{"key":"ref25","unstructured":"FDA grants priority review to UGN-101 for urothelial cancer. (2019). Accessed. August 12, 2025:  https:\/\/www.onclive.com\/view\/fda-grants-priority-review-to-ugn101-for-urothelial-cancer."},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13236040","article-title":"Alterations of chromatin regulators in the pathogenesis of urinary bladder urothelial carcinoma","volume":"13","author":"Hoffmann MJ","year":"2021","unstructured":"Hoffmann MJ, Schulz WA. Alterations of chromatin regulators in the pathogenesis of urinary bladder urothelial carcinoma. Cancers (Basel). 2021, 13:6040. 10.3390\/cancers13236040","journal-title":"Cancers (Basel)"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-22-1444","article-title":"KDM6A loss triggers an epigenetic switch that disrupts urothelial differentiation and drives cell proliferation in bladder cancer","volume":"83","author":"Qiu H","year":"2023","unstructured":"Qiu H, Makarov V, Bolzenius JK, et al.. KDM6A loss triggers an epigenetic switch that disrupts urothelial differentiation and drives cell proliferation in bladder cancer. Cancer Res. 2023, 83:814-29. 10.1158\/0008-5472.CAN-22-1444","journal-title":"Cancer Res"},{"key":"ref28","unstructured":"Zusduri shows durable response in non-muscle-invasive bladder cancer. (2025). Accessed. August 13, 2025: https:\/\/www.curetoday.com\/view\/zusduri-shows-durable-response-in-non-muscle-invasive-bladder-cancer."},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3390\/polym3020779","article-title":"Thermosensitive self-assembling block copolymers as drug delivery systems","volume":"3","author":"Bonacucina G","year":"2011","unstructured":"Bonacucina G, Cespi M, Mencarelli G, Giorgioni G, Palmieri GF. Thermosensitive self-assembling block copolymers as drug delivery systems. Polymers. 2011, 3:779-811. 10.3390\/polym3020779","journal-title":"Polymers"},{"key":"ref30","article-title":"Encapsulation of cells (cellular delivery) using sol-gel systems","author":"Braun S","year":"2011","unstructured":"Braun S.  Encapsulation of cells (cellular delivery) using sol-gel systems. Comprehensive Biomaterials. Ducheyne P (ed): Elsevier, Oxford; 2011. 4:529-43."},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics11120671","article-title":"Poloxamer hydrogels for biomedical applications","volume":"11","author":"Russo E","year":"2019","unstructured":"Russo E, Villa C. Poloxamer hydrogels for biomedical applications. Pharmaceutics. 2019, 11:671. 10.3390\/pharmaceutics11120671","journal-title":"Pharmaceutics"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/9179111","article-title":"Mechanical cues regulate histone modifications and cell behavior","volume":"2022","author":"Hu B","year":"2022","unstructured":"Hu B, Zhou D, Wang H, Hu N, Zhao W. Mechanical cues regulate histone modifications and cell behavior. Stem Cells Int. 2022, 2022:9179111. 10.1155\/2022\/9179111","journal-title":"Stem Cells Int"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1038\/nature10137","article-title":"Role of YAP\/TAZ in mechanotransduction","volume":"474","author":"Dupont S","year":"2011","unstructured":"Dupont S, Morsut L, Aragona M, et al.. Role of YAP\/TAZ in mechanotransduction. Nature. 2011, 474:179-83. 10.1038\/nature10137","journal-title":"Nature"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202400907RR","article-title":"Deciphering the dynamics: exploring the impact of mechanical forces on histone acetylation","volume":"38","author":"Cai J","year":"2024","unstructured":"Cai J, Deng Y, Min Z, Li C, Zhao Z, Jing D. Deciphering the dynamics: exploring the impact of mechanical forces on histone acetylation. FASEB J. 2024, 38:e23849. 10.1096\/fj.202400907RR","journal-title":"FASEB J"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1002\/jbm.a.36942","article-title":"The promise of regenerative medicine in the treatment of urogenital disorders","volume":"108","author":"Keshel SH","year":"2020","unstructured":"Keshel SH, Rahimi A, Hancox Z, Ebrahimi M, Khojasteh A, Sefat F. The promise of regenerative medicine in the treatment of urogenital disorders. J Biomed Mater Res A. 2020, 108:1747-59. 10.1002\/jbm.a.36942","journal-title":"J Biomed Mater Res A"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1007\/s11684-021-0900-3","article-title":"Decellularized extracellular matrix mediates tissue construction and regeneration","volume":"16","author":"Liu C","year":"2022","unstructured":"Liu C, Pei M, Li Q, Zhang Y. Decellularized extracellular matrix mediates tissue construction and regeneration. Front Med. 2022, 16:56-82. 10.1007\/s11684-021-0900-3","journal-title":"Front Med"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.actbio.2014.03.002","article-title":"Characterization of a novel composite scaffold consisting of acellular bladder submucosa matrix, polycaprolactone and Pluronic F127 as a substance for bladder reconstruction","volume":"10","author":"Jang YJ","year":"2014","unstructured":"Jang YJ, Chun SY, Kim GN, et al.. Characterization of a novel composite scaffold consisting of acellular bladder submucosa matrix, polycaprolactone and Pluronic F127 as a substance for bladder reconstruction. Acta Biomater. 2014, 10:3117-25. 10.1016\/j.actbio.2014.03.002","journal-title":"Acta Biomater"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.3390\/mi13020277","article-title":"3D bioprinting of an in vitro model of a biomimetic urinary bladder with a contract-release system","volume":"13","author":"Chae S","year":"2022","unstructured":"Chae S, Kim J, Yi HG, Cho DW. 3D bioprinting of an in vitro model of a biomimetic urinary bladder with a contract-release system. Micromachines (Basel). 2022, 13:277. 10.3390\/mi13020277","journal-title":"Micromachines (Basel)"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2004.08.011","article-title":"Microgrooved fibrillar collagen membranes as scaffolds for cell support and alignment","volume":"26","author":"Vernon RB","year":"2005","unstructured":"Vernon RB, Gooden MD, Lara SL, Wight TN. Microgrooved fibrillar collagen membranes as scaffolds for cell support and alignment. Biomaterials. 2005, 26:3131-40. 10.1016\/j.biomaterials.2004.08.011","journal-title":"Biomaterials"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-55401-9","article-title":"Cell-free biodegradable electroactive scaffold for urinary bladder tissue regeneration","volume":"16","author":"Keate RL","year":"2025","unstructured":"Keate RL, Bury MI, Mendez-Santos M, et al.. Cell-free biodegradable electroactive scaffold for urinary bladder tissue regeneration. Nat Commun. 2025, 16:11. 10.1038\/s41467-024-55401-9","journal-title":"Nat Commun"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.779918","article-title":"KDM6 demethylases and their roles in human cancers","volume":"11","author":"Hua C","year":"2021","unstructured":"Hua C, Chen J, Li S, Zhou J, Fu J, Sun W, Wang W. KDM6 demethylases and their roles in human cancers. Front Oncol. 2021, 11:779918. 10.3389\/fonc.2021.779918","journal-title":"Front Oncol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1101\/2024.10.31.621396","article-title":"Loss of KDM6A-mediated genomic instability and metabolic reprogramming differentially regulates responses to immune checkpoint therapy and chemotherapy in bladder cancer. [Preprint]","author":"Singh P","year":"2024","unstructured":"Singh P, Raychaudhuri D, Chakraborty B, et al.. Loss of KDM6A-mediated genomic instability and metabolic reprogramming differentially regulates responses to immune checkpoint therapy and chemotherapy in bladder cancer. [Preprint]. bioRxiv. 2024, 10.1101\/2024.10.31.621396","journal-title":"bioRxiv"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26157507","article-title":"DNA methylation in bladder cancer: diagnostic and therapeutic perspectives-a narrative review","volume":"26","author":"Puia D","year":"2025","unstructured":"Puia D, Iv\u0103nu\u021b\u0103 M, Pricop C. DNA methylation in bladder cancer: diagnostic and therapeutic perspectives-a narrative review. Int J Mol Sci. 2025, 26:7507. 10.3390\/ijms26157507","journal-title":"Int J Mol Sci"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1090077","article-title":"Pharmacological DNA demethylation: implications for cancer immunotherapy","volume":"5","author":"Roulois D","year":"2016","unstructured":"Roulois D, Yau HL, De Carvalho DD. Pharmacological DNA demethylation: implications for cancer immunotherapy. Oncoimmunology. 2016, 5:e1090077. 10.1080\/2162402X.2015.1090077","journal-title":"Oncoimmunology"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2013.1565","article-title":"Inhibitory effect of valproic acid on bladder cancer in combination with chemotherapeutic agents in vitro and in vivo","volume":"6","author":"Wang D","year":"2013","unstructured":"Wang D, Jing Y, Ouyang S, Liu B, Zhu T, Niu H, Tian Y. Inhibitory effect of valproic acid on bladder cancer in combination with chemotherapeutic agents in vitro and in vivo. Oncol Lett. 2013, 6:1492-8. 10.3892\/ol.2013.1565","journal-title":"Oncol Lett"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1111\/iju.12085","article-title":"Intravesical drug delivery for dysfunctional bladder","volume":"20","author":"Hsu CC","year":"2013","unstructured":"Hsu CC, Chuang YC, Chancellor MB. Intravesical drug delivery for dysfunctional bladder. Int J Urol. 2013, 20:552-62. 10.1111\/iju.12085","journal-title":"Int J Urol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-019-0095-0","article-title":"Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials","volume":"4","author":"Cheng Y","year":"2019","unstructured":"Cheng Y, He C, Wang M, et al.. Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials. Signal Transduct Target Ther. 2019, 4:62. 10.1038\/s41392-019-0095-0","journal-title":"Signal Transduct Target Ther"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.6_suppl.506","article-title":"A pilot study of tazemetostat and pembrolizumab in advanced urothelial carcinoma (ETCTN 10183)","volume":"41","author":"Hussain MHA","year":"2023","unstructured":"Hussain MHA, Kocherginsky M, Singh P, et al.. A pilot study of tazemetostat and pembrolizumab in advanced urothelial carcinoma (ETCTN 10183). J Clin Oncol. 2023, 41:506. 10.1200\/JCO.2023.41.6_suppl.506","journal-title":"J Clin Oncol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.4111\/kju.2013.54.10.645","article-title":"Role of the epithelial-mesenchymal transition in bladder cancer: from prognosis to therapeutic target","volume":"54","author":"Yun SJ","year":"2013","unstructured":"Yun SJ, Kim WJ. Role of the epithelial-mesenchymal transition in bladder cancer: from prognosis to therapeutic target. Korean J Urol. 2013, 54:645-50. 10.4111\/kju.2013.54.10.645","journal-title":"Korean J Urol"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics10080563","article-title":"Multifunctional roles of miR-34a in cancer: a review with the emphasis on head and neck squamous cell carcinoma and thyroid cancer with clinical implications","volume":"10","author":"Kalfert D","year":"2020","unstructured":"Kalfert D, Ludvikova M, Pesta M, Ludvik J, Dostalova L, Kholov\u00e1 I. Multifunctional roles of miR-34a in cancer: a review with the emphasis on head and neck squamous cell carcinoma and thyroid cancer with clinical implications. Diagnostics (Basel). 2020, 10:563. 10.3390\/diagnostics10080563","journal-title":"Diagnostics (Basel)"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1038\/s41563-023-01472-w","article-title":"Hydrogels for RNA delivery","volume":"22","author":"Zhong R","year":"2023","unstructured":"Zhong R, Talebian S, Mendes BB, Wallace G, Langer R, Conde J, Shi J. Hydrogels for RNA delivery. Nat Mater. 2023, 22:818-31. 10.1038\/s41563-023-01472-w","journal-title":"Nat Mater"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2023.1259435","article-title":"Biomaterials-mediated CRISPR\/Cas9 delivery: recent challenges and opportunities in gene therapy","volume":"11","author":"Dubey AK","year":"2023","unstructured":"Dubey AK, Mostafavi E. Biomaterials-mediated CRISPR\/Cas9 delivery: recent challenges and opportunities in gene therapy. Front Chem. 2023, 11:1259435. 10.3389\/fchem.2023.1259435","journal-title":"Front Chem"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-bioeng-122019-121602","article-title":"Integrating biomaterials and genome editing approaches to advance biomedical science","volume":"23","author":"Abdeen AA","year":"2021","unstructured":"Abdeen AA, Cosgrove BD, Gersbach CA, Saha K. Integrating biomaterials and genome editing approaches to advance biomedical science. Annu Rev Biomed Eng. 2021, 23:493-516. 10.1146\/annurev-bioeng-122019-121602","journal-title":"Annu Rev Biomed Eng"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2021.780608","article-title":"Dendriplex-impregnated hydrogels with programmed release rate","volume":"9","author":"Apartsin E","year":"2021","unstructured":"Apartsin E, Venyaminova A, Majoral JP, Caminade AM. Dendriplex-impregnated hydrogels with programmed release rate. Front Chem. 2021, 9:780608. 10.3389\/fchem.2021.780608","journal-title":"Front Chem"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S522421","article-title":"Intravesical tumor-selective mucoadhesive hydrogel for effective chemotherapy in murine model","volume":"20","author":"Zheng B","year":"2025","unstructured":"Zheng B, Chen Z, Sun L, et al.. Intravesical tumor-selective mucoadhesive hydrogel for effective chemotherapy in murine model. Int J Nanomedicine. 2025, 20:7169-83. 10.2147\/IJN.S522421","journal-title":"Int J Nanomedicine"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14133073","article-title":"BCG in bladder cancer immunotherapy","volume":"14","author":"Jiang S","year":"2022","unstructured":"Jiang S, Redelman-Sidi G. BCG in bladder cancer immunotherapy. Cancers (Basel). 2022, 14:3073. 10.3390\/cancers14133073","journal-title":"Cancers (Basel)"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-025-01664-8","article-title":"IL-15: from discovery to FDA approval","volume":"18","author":"Li Z","year":"2025","unstructured":"Li Z, Wrangle J, He K, Sprent J, Rubinstein MP. IL-15: from discovery to FDA approval. J Hematol Oncol. 2025, 18:19. 10.1186\/s13045-025-01664-8","journal-title":"J Hematol Oncol"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200167","article-title":"IL-15 superagonist NAI in BCG-unresponsive non-muscle-invasive bladder cancer","volume":"2","author":"Chamie K","year":"2023","unstructured":"Chamie K, Chang SS, Kramolowsky E, et al.. IL-15 superagonist NAI in BCG-unresponsive non-muscle-invasive bladder cancer. NEJM Evid. 2023, 2:EVIDoa2200167. 10.1056\/EVIDoa2200167","journal-title":"NEJM Evid"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-009-9339-6","article-title":"In vitro dissolution testing with flow-through method: a technical note","volume":"10","author":"Gao Z","year":"2009","unstructured":"Gao Z. In vitro dissolution testing with flow-through method: a technical note. AAPS PharmSciTech. 2009, 10:1401-5. 10.1208\/s12249-009-9339-6","journal-title":"AAPS PharmSciTech"},{"key":"ref60","unstructured":"Guide to USP 71 sterility testing. (2024). Accessed. August 13, 2025: https:\/\/certified-laboratories.com\/blog\/step-by-step-guide-to-usp-71-sterility-testing-methods\/."},{"key":"ref61","unstructured":"How to bill for mitomycin for intravesical solution in NMIBC. (2025). Accessed. August 13, 2025: https:\/\/www.urologytimes.com\/view\/how-to-bill-for-mitomycin-for-intravesical-solution-in-nmibc."},{"key":"ref62","unstructured":"USP sterility tests | Microchem Laboratory. (2024). Accessed. August 12, 2025: https:\/\/microchemlab.com\/test\/usp-71-sterility-tests\/."},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920937950","article-title":"UGN-101 (mitomycin gel): a novel treatment for low-grade upper tract urothelial carcinoma","volume":"12","author":"Kokorovic A","year":"2020","unstructured":"Kokorovic A, Matin SF. UGN-101 (mitomycin gel): a novel treatment for low-grade upper tract urothelial carcinoma. Ther Adv Med Oncol. 2020, 12:1758835920937950. 10.1177\/1758835920937950","journal-title":"Ther Adv Med Oncol"},{"key":"ref64","unstructured":"FDA approves intravesical mitomycin in non-muscle-invasive bladder cancer. (2025). Accessed. August 13, 2025: https:\/\/www.targetedonc.com\/view\/fda-approves-intravesical-mitomycin-in-non-muscle-invasive-bladder-cancer."},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1007\/s11884-019-00543-6","article-title":"The bladder is not sterile: an update on the urinary microbiome","volume":"14","author":"Ackerman AL","year":"2019","unstructured":"Ackerman AL, Chai TC. The bladder is not sterile: an update on the urinary microbiome. Curr Bladder Dysfunct Rep. 2019, 14:331-41. 10.1007\/s11884-019-00543-6","journal-title":"Curr Bladder Dysfunct Rep"},{"key":"ref66","unstructured":"UroGen Pharma. JELMYTO\u00ae (mitomycin) for pyelocalyceal solution. (2024). Accessed: August 13, 2025: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/211728s010lbl.pdf."},{"key":"ref67","unstructured":"Biological evaluation of medical devices\u2014part 1. evaluation and testing within a risk management process. (2020). Accessed: August 13, 2025: https:\/\/array.aami.org\/doi\/10.2345\/9781570207556.ch1."},{"key":"ref68","unstructured":"BioSpace. UroGen presents uTRACT registry at ASCO 2025 Annual Meeting designed to study real-world use of JELMYTO in low-grade upper tract urothelial cancer. (2025). Accessed: August 13, 2025: https:\/\/www.biospace.com\/press-releases\/urogen-presents-utract-registry-at-asco-2025-annual-meeting-designed-to-study...."},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2021.07.003","article-title":"Use of real-world evidence for regulatory approval and coverage of medical devices: a landscape assessment","volume":"24","author":"Timbie JW","year":"2021","unstructured":"Timbie JW, Kim AY, Concannon TW. Use of real-world evidence for regulatory approval and coverage of medical devices: a landscape assessment. Value Health. 2021, 24:1792-8. 10.1016\/j.jval.2021.07.003","journal-title":"Value Health"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003846","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline: 2024 amendment","volume":"211","author":"Holzbeierlein JM","year":"2024","unstructured":"Holzbeierlein JM, Bixler BR, Buckley DI, et al.. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline: 2024 amendment. J Urol. 2024, 211:533-8. 10.1097\/JU.0000000000003846","journal-title":"J Urol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/417624-the-future-of-bladder-cancer-therapies-integrating-hydrogel-scaffolds-for-epigenetic-regulator-delivery","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T15:27:19Z","timestamp":1761751639000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/417624-the-future-of-bladder-cancer-therapies-integrating-hydrogel-scaffolds-for-epigenetic-regulator-delivery"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":70,"URL":"https:\/\/doi.org\/10.7759\/cureus.95675","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,29]]}}}